Serum androgen dynamics in young women aged 18-40 treated with chemotherapy for breast cancer: an observational, multicentric, prospective study in France

Figures & data

Figure 1. Schematic study design. Both testsosterone and androstenedione levels were assayed at diagnosis (sample 0), after chemotherapy completion (sample 6), after 1-year (sample 8) and 2-year (sample 9) follow-up post-chemotherapy. CT, chemotherapy.

Table 1. Demographic, histological and treatment characteristics.

DEMOGRAPHIC CHARACTERISTICS	N = 250
Age (years)	34.8 ± 3.3
< 30 years, % (N)	14% (35)
30-34 years, % (N)	31% (77)
35-40 years, % (N)	55% (138)
Women with children, % (N)	75% (188)
Number of child before diagnosis	2 ± 0.6
Time to have a child >6 months, % (N)	12% (29)
BMI (kg/m2)	23.7 ± 3.3
Current smoker, % (N)	32% (79)
Weight at inclusion (kg)	64.6 ± 0.9
Weight at end of study (kg)	66.2 ± 1.2
Familial history of breast cancer, % (N)	46% (115)
BRCA 1/2 mutation carriers, % (N/number of women tested)	19% (25/132)
HISTOLOGICAL CHARACTERISTICS
Invasive ductal carcinoma, % (N)	92% (229)
Invasive lobular carcinoma, % (N)	5% (13)
Other histological category, % (N)	3% (7)
Grade II-III, % (N)	94% (234)
Positive for hormone receptors, % (N)	68% (169)
HER2 positive, % (N)	28% (69)
Node-positive, % (N)	52%(129)
Breast-conserving surgery, % (N)	54% (136)
TREATMENT CHARACTERISTICS
Neoadjuvant chemotherapy, % (N)	30% (76)
FEC, % (N)	5% (12)
FEC-T, % (N)	88%(221)
TAC, % (N)	0.4% (1)
T, % (N)	6% (14)
Anthracyclin doses (mg/m2)	278 ± 58
Cyclophosphamide doses (mg/m2)	1462 ± 427
Taxane doses (mg/m2)	303 ± 49.36
Number of chemotherapy cycles	6.1 ± 0.9
Trastuzumab co-treatment, % (N)	25% (63)
GnRH analog administration during chemotherapy, % (N)	4% (9)
Ovarian cryopreservation before chemotherapy onset, % (N)	2% (5)
Tamoxifen administration, % (N)	64% (159)

FEC: 5-Fluorouracil, epirubucin, cyclophosphamide; T: Taxanes; AC: Adriamycin, cyclophosphamide.

Results are presented as number of patients and proportions or means ± standard deviation when appropriate.

Figure 2. Evolution and relative variation of serum androstenedione (A,C) and total testosterone levels (B,D) during chemotherapy and 24-month follow-up after chemotherapy completion. *:p < 0.05.

Data availability statement

Data can be made available upon reasonable request, after evaluation by the corresponding author.